Details of the Drug Combination

General Information of Drug Combination (ID: DCTVW0K)

Drug Combination Name

Vinflunine Topetecan

Indication

Disease Entry	Status	REF
Anaplastic large cell lymphoma	Investigative	[1]

Component Drugs

Vinflunine DMTJAEP

Topetecan DMAE6LK

Small molecular drug

2D MOL

3D MOL

High-throughput Screening Result

Testing Cell Line: SR

Zero Interaction Potency (ZIP) Score: 3.07

Bliss Independence Score: 3.27

Loewe Additivity Score: 0.64

LHighest Single Agent (HSA) Score: 5.08

Molecular Interaction Atlas of This Drug Combination

Molecular Interaction Atlas (MIA)

Indication(s) of Vinflunine

Disease Entry	ICD 11	Status	REF
Solid tumour/cancer	2A00-2F9Z	Approved	[2]

Indication(s) of Topetecan

Disease Entry	ICD 11	Status	REF
Small-cell lung cancer	2C25.Y	Approved	[3]

Topetecan Interacts with 1 DTT Molecule(s)

DTT Name	DTT ID	UniProt ID	Mode of Action	REF
DNA topoisomerase I (TOP1)	TTGTQHC	TOP1_HUMAN	Inhibitor	[4]
------------------------------------------------------------------------------------

Test Results of This Drug Combination in Other Disease Systems

Indication	DrugCom ID	Cell Line	Status	REF
Adult T acute lymphoblastic leukemia	DC9FFUV	MOLT-4	Investigative	[1]
Adenocarcinoma	DCFFC1Z	SW-620	Investigative	[5]
------------------------------------------------------------------------------------

References

1	CheMBL Affinity Phenotypic Cellular Interaction Assay ID: CHEMBL1125966
2	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
3	FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (NDA) 020671.
4	Clinical pipeline report, company report or official report of GlaxoSmithKline (2009).
5	CheMBL Affinity Phenotypic Cellular Interaction Assay ID: CHEMBL1125976